Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Anxiety
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Anxiety
    Risperidone With Standard Therapy Reduces Relapses of Bipolar Episode Regardless of Episode Type: Presented at CINP - (DGDispatch)
    General Practitioners Prescribing Potentially Inappropriate Psychotropic Medications to Older Patients With Generalised Anxiety: Presented at CINP - (DGDispatch)
    TopAbstracts in Anxiety 07/09/2008 - (DGNews)
    TopAbstracts in Anxiety 06/25/2008 - (DGNews)
    Pregabalin Effective for Fibromyalgia Pain Regardless of Patient Anxiety or Depression: Presented at EULAR - (DGDispatch)

    News archive

     Recent webcasts/CME - Anxiety
    • Understanding and Managing the Fibromyalgia Syndrome
    • Accurate Diagnosis of Fibromyalgia Is Essential for Effective Management
    • Functional Neuroimaging Studies Illuminate Mechanisms Underlying Development of Fibromyalgia
    • Pharmacologic and Behavioral Approaches Expand Treatment Options for Fibromyalgia
    • Prevalence and Associated Factors for Suicidal Ideation and Behaviors in Obsessive-Compulsive Disorder

      Webcasts/CME archive

       Recent cases - Anxiety
        Recurrence of Suicidal Ideation Due to Treatment with Antidepressants in Anxiety Disorder: A Case Report
        Persistent Tardive Rebound Panic Disorder, Rebound Anxiety and Insomnia Following Paroxetine Withdrawal: a Review of Rebound-Withdrawal Phenomena
        Olfactory Reference Syndrome: Diagnostic Criteria and Differential Diagnosis
        Comedication with Sertraline and Phenprocoumon in Two Patients with Anxiety Disorders
        Self-Hypnosis for Anxiety Associated with Severe Asthma: A Case Report

        Cases archive
          




        my personal edition > anxiety > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        APA: Venlafaxine XR and Paroxetine Combination Improves Physiological Symptoms of Panic Disorder and Social Anxiety Disorder

        By Bruce Sylvester

        SAN FRANCISCO, CA -- May 25, 2003 -- Venlafaxine XR and paroxetine in combination elicited significant improvements in the physical symptoms associated with panic disorder (PD) and social anxiety disorder (SAD), researchers reported May 22nd here at the Annual Meeting of the American Psychiatric Association.

        "We found that patients diagnosed with either of these disorders characteristically suffer from significant physiological distress, and it is often the reason they seek help in the first place," said lead investigator and presenter Rajiv Mallick, PhD, a researcher at Wyeth Research, in Collegeville, Pennsylvania. "It is heartening to note that as we address the primary symptoms of [these] disorders, we might also be able to simultaneously address some of the commonly experienced physical distress."

        Dr. Mallick and his research team analysed pooled data on 958 subjects from two randomised, double-blind, placebo-controlled PD studies (one included a paroxetine control group) of venlafaxine XR 75 mg, 150 mg, or flexible dosages. The treatment phase lasted 10 to 12 weeks. All subjects met Diagnostic and Statistical Manual - Revision IV (DSM-IV) criteria for PD.

        The patient-reported Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) assessed treatment-related changes in physical symptoms. This tool measures eight subscales: physical health/activities, as well as subjective feelings of well-being, work, household duties, school/course work, leisure time, social relations, and general well-being. The questionnaire also has two subscales on satisfaction with medication and overall life satisfaction.

        Investigators measured response to treatment using a 5-point Likert scale, with increasing scores from baseline indicating improved physical functioning.

        The researchers also analysed pooled data on 1,372 subjects from four randomised, double-blind, placebo-controlled SAD studies, including two paroxetine-controlled studies, of flexible-dose venlafaxine XR. The treatment phases of each study lasted 10 weeks. All subjects met the DSM-IV SAD criteria at baseline. Outcomes included the physiological-arousal subscale of the Social Phobia Inventory (SPIN) and the total SPIN score. The subscale includes four important symptoms of SAD patients: blushing, sweating, palpitations and shaking/trembling, as well as additional areas measuring non-somatic factors such as fear and avoidance.

        The investigators reported that, "In PD, venlafaxine XR and paroxetine were associated with greater improvement versus placebo on the physical health/activities subscale [P<0.0001 and P=0.0004, respectively] and on most other subscales [venlafaxine XR 8 out of 9, paroxetine 5 out of 9]."

        "In SAD, improvement on the physiological arousal sub-scale and total SPIN score [all P<0.0001] was greater with venlafaxine XR and paroxetine than with placebo." Dr. Mallick added. "We saw enough changes from baseline to end point in these studies to say that venlafaxine XR effectively ameliorates physiological symptoms in acute-term treatment in both PD and SAD, and that there are similar if slightly more modest results for paroxetine."

        This study was supported by Wyeth Research.


        [Study title: Improvement in Physical Symptoms in Select Anxiety Disorders. Abstract NR797]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send